

# Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	24 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Participant must be 2 to < 18 years of age at the time of signing the informed consent or assent.
- Stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for e 3 months prior to Screening with no planned change during Screening through Week 106.
- UPCR e 1.0 g/g from the mean of 3 first morning voids (FMV) collected within 1 week during the Screening Period
- Estimated GFR e 30 mL/min/1.73 m<sup>2</sup> during Screening
- Meningococcal infection vaccine
- ... and 3 more (see full listing online)

### Exclusion (14)

- Diagnosis of rapidly progressive glomerulonephritis
- Secondary forms of IgAN not in the context of primary IgAN or IgAV
- Concomitant clinically significant renal disease other than IgAN or IgAVN
- Clinical remission of IgAN/IgAVN or clinically significant improvement in proteinuria within the last 6 months.
- Uncontrolled diabetes mellitus with HbA1c > 8.5%
- ... and 9 more (see full listing online)

## Locations (14 total)

---

Research Site, Palo Alto, California, United States  
Research Site, Aurora, Colorado, United States  
Research Site, Beijing, China  
... and 11 more locations